Back to Search
Start Over
Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
- Source :
- Annals of Allergy, Asthma & Immunology; July 2023, Vol. 131 Issue: 1 p44-51.e4
- Publication Year :
- 2023
-
Abstract
- Type 2 inflammation is common in children with asthma. Dupilumab, a human antibody, blocks the signaling of interleukin -4 and -13, key and central drivers of type 2 inflammation. In the LIBERTY ASTHMA VOYAGE (NCT02948959) study, dupilumab reduced severe asthma exacerbations and improved lung function in children aged 6 to 11 years with uncontrolled, moderate-to-severe asthma.
Details
- Language :
- English
- ISSN :
- 10811206
- Volume :
- 131
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Annals of Allergy, Asthma & Immunology
- Publication Type :
- Periodical
- Accession number :
- ejs62593724
- Full Text :
- https://doi.org/10.1016/j.anai.2023.03.014